SLU Study: Head and Neck Cancer Diagnostic Delays Linked to Antibiotics Despite Clinical Practice Guidelines
ST. LOUIS — Researchers at Saint Louis University School of Medicine say diagnostic delays frequently occur in patients with undiagnosed head and neck cancer (HNC) and are calling for improved dissemination of current clinical practice guidelines in a new paper published Aug. 24 in JAMA Otolaryngology – Head & Neck Surgery.
Researchers found that undiagnosed HNC patients with neck swelling and other symptoms are frequently prescribed antibiotics, rather than following current clinical guidelines recommending evaluation for cancer, which can delay diagnosis and complicate treatment for their cancer.
Sean Massa, M.D.
Sean Massa, M.D., associate professor of otolaryngology at SLU, is the paper’s senior author. Massa, a surgeon who treats HNC patients and other tumors of the head and neck, says diagnostic delays can translate into requiring more aggressive treatments with more toxicities and a lower cure rate.
“ENT doctors usually are quite familiar with this cancer diagnosis and can use their training and tools to parse out whether it be symptoms caused by cancer or some other cause,” Massa said. “But it's much more challenging for primary care doctors to make that determination, and I worry that this knowledge is not being disseminated to the broader medical community.”
Researchers analyzed temporal trends, associated factors and diagnostic times between antibiotic prescribing before HNC diagnosis. They found that the number of patients receiving antibiotics leading up to cancer diagnosis has not changed after the release of clinical practice guidelines. Researchers say they hope to see that rate decrease.
In this cohort study of 7,811 patients with HNC, 15.6% received an antibiotic within three months of HNC diagnosis, resulting in a statistically significant 21.1% longer time to HNC diagnosis. This prescribing rate was static over the study period, and specific clinical and oncologic factors were associated with higher antibiotic prescription rates.
Researchers used data from a deidentified electronic health records data set from Jan. 1, 2011, to Dec. 31, 2018. Data analysis was conducted from May 1 to Nov. 9, 2022. Researchers at SLU’s AHEAD Institute maintained the data resource and supported the study through analytics and data management.
Other authors include James A. Gallogly, M.D., Austin T. Armstrong, Henry Ideker, M.D., Ronald J. Walker, M.D., of Department of Otolaryngology – Head and Neck Surgery, Saint Louis University School of Medicine; Joanne Salas, MPH, of the Department of Family and Community Medicine at Saint Louis University, Harry S. Truman Veterans Administration Medical Center, Columbia, Mo., and the Advanced HEAlth Data (AHEAD) Research Institute at SLU; Matthew C. Simpson, MPH, of Department of Otolaryngology – Head and Neck Surgery, Saint Louis University School of Medicine, and the Advanced HEAlth Data (AHEAD) Research Institute at SLU; and Jennifer V. Brinkmeier, M.D., Department of Otolaryngology – Head and Neck Surgery, Washington University School of Medicine in St. Louis.
About AHEAD Institute
The Advanced HEAlth Data (AHEAD) Research Institute at Saint Louis University is a comprehensive center for data-driven innovation and research to improve the health of individuals and populations. The institute brings together researchers from various fields and disciplines to help improve patient and population health, advance the quality of health care and decrease health care costs. The new institute will utilize and develop data resources, novel analytic methods, predictive modeling, machine learning, and integrated wearable health devices and collaborate with national research networks.
About SLU School of Medicine
Established in 1836, Saint Louis University School of Medicine has the distinction of awarding the first medical degree west of the Mississippi River. The school educates physicians and biomedical scientists, conducts medical research, and provides health care on a local, national and international level. Research at the school seeks new cures and treatments in five key areas: cancer, liver disease, heart/lung disease, aging and brain disease, and infectious diseases.
Latest Newslink
- SLU Professor's Taco Fundraiser to Support Tornado Relief EffortsSaint Louis University chef Daniel Brewer, MS, RDN, is hosting a special fundraising event at his home this weekend featuring an innovative taco menu that draws from a variety of global influences. Proceeds will benefit Action St. Louis.
- Saint Louis University Vaccine Center Recruits Healthy Participants for Flu Human Challenge StudyStudy participants will be infected with the influenza virus while under the care of a medical team in order to learn more about how healthy people’s immune systems respond to an influenza infection.
- SLU/YouGov Poll: Missouri Voters Sweet on Kansas City BBQIn February 2025, the SLU/YouGov Poll asked 900 likely Missouri voters which regional style of American barbecue was their favorite. Kansas City style came out on top, with 41 percent of voters selecting it as their favorite barbecue style, more than double the 17 percent who favored St. Louis style.
- SLU President Tells Class of 2025 to Enjoy the JourneySaint Louis University President Fred P. Pestello, Ph.D., never planned on a career in higher education. During his commencement address Saturday morning in front of a packed crowd at Chaifetz Arena, Pestello said that when he was the one graduating from college 51 years ago, he wanted to be a radio host. Along the way, things changed, and he ended up having a lengthy career in education. As he prepares to step down as SLU's 33rd president at the end of June, he told the Class of 2025 about how his plans changed early and often.
- SLU Vaccine Center Will Enroll Healthy Volunteers in West Nile Virus Clinical TrialSaint Louis University's Center for Vaccine Development will enroll up to 30 adult volunteers in a clinical trial to study the safety and immune response elicited by a new investigational vaccine for West Nile virus. Currently, there is no approved vaccine or treatment for illness caused by West Nile virus. A previous study of an earlier version of this vaccine showed the vaccine was safe and well-tolerated. Building on these findings, this new study will assess an updated version of the vaccine.
- SLU Doctoral Student and Augustinian Friar Shares Memories of Time Spent with Pope Leo XIVWhen Cardinal Robert Prevost stepped out onto the balcony in St. Peter’s Square as Pope Leo XIV on Thursday, Saint Louis University doctoral student Fr. Jack Tierney O.S.A. cheered along with the rest of the world’s Catholics. Tierney is a member of the Midwest Augustinians, the same religious Order that produced Pope Leo XIV. Their paths frequently crossed as brother friars.